- Home
- PAX vs OCS Comparison
PAX vs OCS Comparison
Compare PAX & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PAX | OCS |
|---|---|---|
| Founded | 1988 | 2003 |
| Country | Cayman Islands | Switzerland |
| Employees | N/A | 60 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | PAX | OCS |
|---|---|---|
| Price | $11.17 | $11.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $18.00 | ★ $42.00 |
| AVG Volume (30 Days) | ★ 796.0K | 473.1K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.81% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.99 | $466.06 |
| Revenue Next Year | $16.52 | $479.73 |
| P/E Ratio | $25.65 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.56 | $10.52 |
| 52 Week High | $17.80 | $34.48 |
Technical Indicators
Market Signals| Indicator | PAX | OCS |
|---|---|---|
| Relative Strength Index (RSI) | 50.38 | 33.01 |
| Support Level | $11.04 | $10.52 |
| Resistance Level | $11.38 | $21.82 |
| Average True Range (ATR) | 0.24 | 0.72 |
| MACD | 0.04 | 0.19 |
| Stochastic Oscillator | 60.75 | 7.14 |
Price Performance
Historical ComparisonAbout PAX Patria Investments Limited
Patria Investments Ltd is an alternative asset management firm specializing in resilient sectors across select regions. It seeks to provide world-wide and Latin American investors with attractive investment products that allows portfolio diversification and consistent returns. The group promotes inclusive and sustainable development in the Asset Classes: Private Equity, Private Equity Solutions, Credit, Real Estate, Infrastructure, and Public Equities Main sectors: Agribusiness, Power & Energy, Healthcare, Logistics & Transportations, Food & Beverage and Digital & Tech Services Investment Regions.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.